IMRT Usage and Cost Related to Geography And Medicare Reimbursement Policy, Study Finds
Aflibercept Improves Overall Survival In Second-Line Colorectal Cancer Setting
Motesanib Does Not Improve OS; Study Doesn’t Meet Primary Endpoint
Beta Blockers Negate Harmful Recurrence Risks of ACE Inhibitors
Study Validates “PEM” Scans As Biopsy Guidance Method
Prostatectomy Lowers Death Risk Compared to Watchful Waiting
Postponed Surgery For Low-Grade Prostate Cancer Adds No Risk
Acupuncture Can Relieve Side Effects of Hormone Treatment
Selumetinib Displays Positive Results, 60% with Stable Disease
National Health Organizations Warn of Risks in Indoor Tanning
Clinical Trials Approved By NCI CTEP Last Month
SWOG Launching New Study Based on Recurrence Test Scores
Centocor Withdraws Yondelis After FDA Calls for New Study
FDA Approves New Device For Glioblastoma Multiforme
EU Gives Marketing Approval For HBV Sequencing Test
Roche Markets CMV Test in Europe
Trending Stories
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- How George Tidmarsh crossed the FDA-industry Rubicon
- Cancer centers adapt to life without site visits as NIH changes CCSG review
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
- How GLP-1RA drugs are reshaping patient physiology and the future of oncology
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval
